Results 11 to 20 of about 2,193 (158)

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.

PLOS Global Public Health, 2023
Bedaquiline (B), pretomanid (Pa) and linezolid (L) are key components of new regimens for treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the global prevalence of resistance to these drugs and the impact of ...
Juliano Timm, Anna Bateson, Priya Solanki, Ana Paleckyte, Adam A Witney, Sylvia A D Rofael, Stella Fabiane, Morounfolu Olugbosi, Timothy D McHugh, Eugene Sun   +9 more
doaj   +4 more sources

DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid

Nature Communications, 2023
Mycobacterium tuberculosis is one of the global leading causes of death due to a single infectious agent. Pretomanid and delamanid are new antitubercular agents that have progressed through the drug discovery pipeline.
Katherine A. Abrahams, Sarah M. Batt, Sudagar S. Gurcha, Natacha Veerapen, Ghader Bashiri, Gurdyal S. Besra   +5 more
doaj   +3 more sources

Prevalence and genetic basis of Mycobacterium tuberculosis resistance to pretomanid in China

Annals of Clinical Microbiology and Antimicrobials
Background Pretomanid is a key component of new regimens for the treatment of drug-resistant tuberculosis (TB) which are being rolled out globally. However, there is limited information on the prevalence of pre-existing resistance to the drug. Methods To
Bing Zhao, Huiwen Zheng, Juliano Timm, Zexuan Song, Shaojun Pei, Ruida Xing, Yajie Guo, Ling Ma, Feina Li, Qing Li, Yan Li, Lin Huang, Chong Teng, Ni Wang, Aastha Gupta, Sandeep Juneja, Fei Huang, Yanlin Zhao, Xichao Ou   +18 more
doaj   +3 more sources

Evaluating treatment outcomes stratified by regimen among drug-resistant TB patients in Sierra Leone [PDF]

Public Health Action
SETTING: Sierra Leone has a high burden of drug-resistant TB (DR-TB), managed at three treatment centres. OBJECTIVE: To compare treatment success between BPaL (bedaquiline, pretomanid, and linezolid)/BPaLM (bedaquiline, pretomanid, linezolid, and ...
J.A. Koroma, B.D. Fofanah, D. Nair, E.M. Kamau, I.F. Kamara, M.A. Sesay, I.S. Turay, N. Sesay, F. Kanu, W.K. Lahai, J.S. Kanu, A.T. Koroma, F. Fornah, A.L. Seisay, S.S. Bailor, R. Harding, S. Emezue, G.B. Tefera, G. Ameh, M. Mazzi, S. Lakoh, M. Mahmoud   +21 more
doaj   +2 more sources

Refined understanding of the impact of the Mycobacterium tuberculosis complex diversity on the intrinsic susceptibility to pretomanid

Microbiology Spectrum
Previous work reported unprecedented differences in the intrinsic in vitro susceptibility of the Mycobacterium tuberculosis complex (MTBC) to pretomanid (Pa) using the Mycobacteria Growth Indicator Tube (MGIT) system.
Praharshinie Rupasinghe, Leen Rigouts, Claudio U Koser   +2 more
exaly   +3 more sources

Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials [PDF]

IJTLD Open
BACKGROUND: In STAND and SimpliciTB, clinical trials for drug-susceptible TB, regimens containing pretomanid, pyrazinamide, and other agents (PaZX) had more hepatotoxicity than the standard-of-care regimen of isoniazid, rifampicin, pyrazinamide, and ...
J. Nedelman, M. Li, M. Olugbosi, R. Bruning-Barry, J. Ambroso, M. Cevik, S. Gillespie, D.J. Sloan, M. Beumont, E. Sun   +9 more
doaj   +2 more sources

Pretomanid: The life-saving drug to combat Pakistan’s TB crisis

Journal of the Pakistan Medical Association
Madam, Tuberculosis (TB) is a disease that can be prevented and is typically curable. Yet, until COVID-19 took over, TB was the most infectious disease in the world.
Rai Muhammad Umar Khan, Muhammad Hamza Amir, Abdul Rehman   +2 more
doaj   +3 more sources

Pretomanid for tuberculosis: a systematic review [PDF]

Clinical Microbiology and Infection, 2022
Outcomes of treatment of tuberculosis patients with regimens including pretomanid have not yet been systematically reviewed.To appraise existing evidence on efficacy and safety of pretomanid in tuberculosis.Pubmed, clinicaltrials.gov. and Cochrane library.Quantitative studies presenting original data on clinical efficacy or safety of pretomanid ...
Tinne, Gils, Lutgarde, Lynen, Bouke C, de Jong, Armand, Van Deun, Tom, Decroo   +4 more
openaire   +2 more sources

Whole genome sequencing-based detection of extensively drug-resistant tuberculosis from Ethiopia [PDF]

Communications Medicine
Background Rapid and accurate detection of extensively drug-resistant tuberculosis is crucial for effective intervention. Next-generation sequencing technologies have been recommended to rapidly and accurately detect resistance to second-line anti-TB ...
Getu Diriba, Hilina Mollalign, Abyot Meaza, Melak Getu, Betselot Zerihun, Ayinalem Alemu, Biniyam Dagne, Yeshiwork Abebaw, Atsbaha Gebreegziabxier Weldemariam, Chala Bashea, Abraham Ali, Getachew Seid, Muluwork Getahun, Michael Hailu, Amanuel Wondimu, Tsegaye Getachew, Andargachew Kumsa, Taye Letta, Atlabachew Liaulseged, Negga Asamene Abera, Zelalem Abate, Ephrem Alemu, Feyissa Challa, Gemechu Tadesse, Saro Abdella, Getachew Tollera, Mesay Hailu Dangisso   +26 more
doaj   +2 more sources

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys

Toxicology Reports, 2022
Pretomanid is a nitroimidazooxazine antimycobacterial drug that was approved in more than 10 countries as part of a three-drug, all oral regimen, consisting of bedaquiline, pretomanid, and linezolid (BPaL) for 6-months treatment of adults with pulmonary ...
Rebecca Bruning-Barry, Jeffrey L. Ambroso, John Dillberger, Tian J. Yang   +3 more
doaj   +1 more source